US FDA cleared IND application allowing for the start of Ph 1 trial of SP-3164 in patients with R/R NHL

“US Food and Drug Administration has cleared its investigational new drug (IND) application allowing for the start of a Phase I trial of SP-3164 in patients with relapsed or refractory non-Hodgkin lymphoma. In the trial, expected to begin in the second half of this year, Salarius will also evaluate a gene signature for selecting patients who may respond well to the second-generation targeted protein degrader SP-3164. The dose-escalation portion of the study will involve patients with non-Hodgkin lymphoma, and in a second portion of the study, researchers will assess the activity of the drug in patients with diffuse large B-cell lymphoma, Salarius CEO David Arthur said in a statement.”
Share:
More News
“We are encouraged by the progress of our clinical trial and remain focused on our goal to develop innovative therapies that can address glioblastoma and other cancers. Although we are unable to provide detailed information at this stage, we are excited about the continued advancement of this important program,” said
“We are disappointed in the outcome of the RELATIVITY-098 trial and that LAG-3 inhibition in the adjuvant setting did not lead to the same improved efficacy outcomes seen in advanced melanoma,” said Jeffrey Walch, M.D., Ph.D., vice president, Opdualag global program lead, Bristol Myers Squibb. “Patients whose tumors are completely
Ahsan Arozullah, M.D., M.P.H., Senior Vice President, Head of Oncology Development, Astellas said, “The combination of enfortumab vedotin and pembrolizumab was the first approval to offer an alternative to platinum-containing chemotherapy, which had been the standard of care for first-line locally advanced or metastatic urothelial cancer for decades. We are
“U.S. FDA has accepted for review the resubmission of the BLA for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last